Get the Stockscreener App
0.00
100.00%
-7.35
Ataibeckley Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
See More
Previous Close:
$7.35
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$2.73B
Revenue:
$3.49M
Net Income/Loss:
$-663.48M
P/E Ratio:
0.00
EPS:
-2.2387
Net Cash Flow:
$-115.08M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$7.40
52-Week Range:
$0.00
$7.45
Ataibeckley Inc Stock (ATAI) Company Profile
Name
Ataibeckley Inc
Sector
Industry
Phone
1 929 207 2670
Address
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Compare ATAI vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
0.00 | 2.73B | 3.49M | -663.48M | -115.08M | -2.2387 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Deutsche Bank | Buy |
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Ataibeckley Inc Stock (ATAI) Latest News
Why Is ATAI Stock Soaring 59% After-Hours? - Stocktwits
Lilly completes acquisition of AtaiBeckley for mental health drugs By Investing.com - Investing.com India
Form 8K ATAI Beckley Inc For: 11 September By Investing.com - Investing.com South Africa
Eli Lilly now owns AtaiBeckley (NASDAQ: ATAI) after merger - Stock Titan
Nasdaq removes AtaiBeckley (Nasdaq: ATAI) common stock from listing - Stock Titan
Lilly Completes AtaiBeckley Acquisition to Expand Mental Health Pipeline - citybiz
Eli Lilly Closes $6.75-Per-Share AtaiBeckley Buyout - Minichart
Eli Lilly completes acquisition of AtaiBeckley, initiates delisting from Nasdaq By Investing.com - Investing.com Canada
After Eli Lilly deal, AtaiBeckley (ATAI) pulls remaining employee stock from SEC registration - Stock Titan
Eli Lilly (NYSE: LLY) now owns all of AtaiBeckley (NASDAQ: ATAI) - Stock Titan
Eli Lilly completes acquisition of AtaiBeckley, initiates delisting from Nasdaq - Investing.com
Eli Lilly Completes Acquisition of AtaiBeckley - marketscreener.com
AtaiBeckley Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Lilly completes acquisition of AtaiBeckley for mental health drugs - Investing.com
Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions - Eli Lilly
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report? - Yahoo Finance
COSCIENS Biopharma Inc. acquired IntelGenx Technologies Corp. from AtaiBeckley Inc. for $9 million. - marketscreener.com
ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too? - Stocktwits
AtaiBeckley Inc. (ATAI) News, Articles, Events & Latest Updates - Stocktwits
AtaiBeckley Inc.(NasdaqGM: ATAI) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
AtaiBeckley Inc.(NasdaqGM: ATAI) dropped from S&P TMI Index - marketscreener.com
AtaiBeckley Inc.(NasdaqGM: ATAI) dropped from S&P Global BMI Index - marketscreener.com
AtaiBeckley Inc.(NasdaqGM: ATAI) dropped from NASDAQ Biotechnology Index - marketscreener.com
Shareholders clear Lilly merger for AtaiBeckley (ATAI), with closing still subject to conditions - Stock Titan
ATAI: Merger agreement with Eli Lilly and Company received shareholder approval - TradingView
ATAI: Merger agreement with Eli Lilly and Company approved by shareholders; all proposals passed - TradingView
AtaiBeckley Inc.(NasdaqGM: ATAI) dropped from Russell 2000 Value Benchmark - marketscreener.com
Why Did AAPL, ATAI, UNH Stocks Jump To 52-Week Highs Today? - Stocktwits
Atai Beckley (NASDAQ:ATAI) Clears Minervini Trend Template and High-Growth Momentum Screen - ChartMill
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates A - The National Law Review
Jim Cramer Isn't Sure If There’s Upside In This Health Care Stock - Benzinga
AtaiBeckley merger with Eli Lilly clears HSR waiting period; UK, Australia reviews progressing - TradingView
Ataibeckley Hart-Scott-Rodino Waiting Period For Eli Lilly Merger Expired August 28 - TradingView
Lilly–AtaiBeckley (NASDAQ: ATAI) merger clears hurdles, not the finish line - Stock Titan
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc.ATAI - Sahm
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates - GuruFocus
Eli Lilly-AtaiBeckley deal approved in Australia - MLex
ATAI Beckley earnings up next in final report before acquisition - Investing.com
How Investors Are Reacting To AtaiBeckley (ATAI) Rising Revenue But Deepening Net Losses - simplywall.st
AtaiBeckley (ATAI) Price: Ends Up by 0.96% at $7.36 at the Close; Levels: Support at $6.99 and Resistance at $7.73 Frame the Range for the Current SessionHot Stock Picks - Vinanet
Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders? - TradingView
AtaiBeckley(ATAI) Stock Options Chain | Quotes & News - Moomoo
Oppenheimer Downgrades AtaiBeckley to Market Perform From Outperform - marketscreener.com
Oppenheimer Downgrades AtaiBeckley(ATAI.US) to Hold Rating - Moomoo
Biotech Stocks At 52-Week HighsETON +44%, DXCM, ORKA, CON, ATAI - RTTNews
AtaiBeckley (ATAI) Q1 2026 Earnings: 23% EPS Beat Offsets Pre-Revenue ProfileCash Flow Report - Vinanet
ATAI Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock Jumps 28%EPS Growth Report - Vinanet
ATAI Beckley earnings beat by $0.03, revenue topped estimates - Investing.com South Africa
ATAI Q1 2026 Earnings: Narrower Loss Beats Estimates by 23% as Shares Surge 28%Analyst Coverage Count - Vinanet
Atai stock hits 52-week high of $7.26 - Investing.com
ATAI Q1 2026 Earnings: Narrower-than-Expected Loss Drives 28% Stock Move Amid Pre-Revenue StatusEarnings Expansion Phase - Vinanet
Ataibeckley Inc Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):